Immunogenicity, Safety, and Cross‐Reactivity of an Inactivated, Adjuvanted, Prototype Pandemic Influenza (H5N1) Vaccine: A Phase II, Double‐Blind, Randomized Trial
Open Access
- 15 April 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 48 (8) , 1087-1095
- https://doi.org/10.1086/597401
Abstract
Background. Avian influenza A virus H5N1 has the potential to cause a pandemic. Adjuvants and whole-virion vaccines are regarded as antigen sparing fKeywords
This publication has 1 reference indexed in Scilit:
- Evolution of H5N1 Avian Influenza Viruses in AsiaEmerging Infectious Diseases, 2005